Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Jorgensen

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Blood|January 10, 2016
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Audrey V Lamb, Susan O'Brien, et al.
The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.
Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.
American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Cancer|October 12, 2018
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageElias Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 25, 2015
General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood TransplantationRima M Saliba, Katayoun Rezvani, Ann Leen, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Journal of Hematology & Oncology|May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaHagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Blood|January 10, 2016
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Audrey V Lamb, Susan O'Brien, et al.
The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.
Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.
American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Cancer|October 12, 2018
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageElias Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 25, 2015
General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood TransplantationRima M Saliba, Katayoun Rezvani, Ann Leen, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Journal of Hematology & Oncology|May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaHagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Pageof 5